Powered by

GlycoMimetics shares nearly cut in half as Pfizer-partnered phase 3 drug flops

Aug 05, 2019 - FierceBiotech
Financial Results

Sneaking in the bad news after hours on a Friday (a Bio-Twitter bugbear) still wasn't under the radar enough to help stop the hemorrhaging of GlycoMimetics' shares.

The bad news: Its pivotal phase 3 sickle cell disease asset rivipansel, being developed by Pfizer in a deal dating all the way back to 2011, failed its primary and key secondary endpoints in the so-called RESET trial.

This test was set up to see how well and how safely rivipansel, a pan-selectin antagonist, worked in pati...